JHS Svendgaard Laboratories share price & results
- Jun 2026
- Jun 2026
Contract (private-label) manufacturer of oral-care products — toothbrushes, toothpastes, mouthwash and talcum powder — running India's only fully integrated toothbrush-and-toothpaste facility.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 30.4 | +29.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 6.8 | −0.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.1 | +2.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | -1.09 | +10.0 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -10.94 | +5.4 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 19.43 | −18.7 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −41.5% 1Y
1Y: ₹13.56 on 24 Oct 2025 → ₹7.93. High ₹13.56 (24 Oct 2025), low ₹6.55 (30 Mar 2026).
- Previous close
- ₹8.18
- Market cap
- ₹92 Cr
- 52-week range
- ₹6.55 – ₹13.54
- One year
- −41.43%
- Return on equity (TTM to Jun 2026)
- -1.09%
Overview
- Symbol
- NSE:JHS
- Exchange
- NSE
- Currency
- INR
What JHS Svendgaard Laboratories Limited does
Based on the company's own presentations, annual report and earnings calls.
JHS Svendgaard Laboratories manufactures oral-care and personal-care products — toothbrushes, toothpastes, mouthwashes, denture tablets, whitening gels and talcum powder — on a contract/private-label basis for FMCG brands such as Dabur, Patanjali, Amway, HUL (Close Up), Reliance Consumer Products and Jyothy Labs. All production is concentrated at one integrated campus in Kala Amb, Himachal Pradesh, combining mechanical (toothbrush moulding/bristling) and chemical (toothpaste/liquid) manufacturing under one roof. It earns as an OEM/private-label supplier rather than through its own retail brand, and has recently diversified into talcum powder and expanded export sales into the US and Middle East.
Segments
- Toothbrushes
- Toothpastes
- Mouthwash & denture tablets
- Talcum powder
- Manufacturing campus
- Kala Amb, Himachal Pradesh — 20 acres, 6 integrated units (3 toothbrush, 2 toothpaste, 1 talcum)
- Toothbrush injection-moulding machines
- ~64 (33+4 horizontal, 27 vertical, 4 rotary) from Demag, Cincinnati, L&T, Haitian
- Bristling/tufting machines
- 74 (Zahoransky Germany, Boucherie Belgium, Alpha Plus Taiwan)
- Toothpaste high-speed filling lines
- 7+1 lines, 120–150 TPM (Wimco)
- Talcum manufacturing capacity
- Expanded from 3,000 to 10,000 units in FY25
- Export markets
- 9+ countries (incl. Mongolia, China, Iran, Saudi Arabia, Bangladesh, Thailand, Ethiopia, Australia), plus new entries into the US (Orazen Inc.) and Middle East (Classico Brands) in FY25
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +3% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 20 | 23 | 25 | 23 | 22 | 23 | 33 | 30 |
| Expenses | 21 | 22 | 31 | 22 | 21 | 22 | 34 | 28 |
| Operating profit | -1 | 0 | -5 | 2 | 1 | 2 | -2 | 2 |
| Operating margin | −4.3% | 1.1% | −21.4% | 7.1% | 4.1% | 7.2% | −5.0% | 6.8% |
| Other income | 1 | 0 | -1 | 1 | 1 | 1 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | -2 | -2 | -9 | 1 | -0 | 0 | -3 | 0 |
| Tax rate | 398.1% | 15.8% | −23.1% | −69.3% | 1800.0% | −887.5% | 19.7% | −1716.7% |
| Net profit | -10 | -2 | -7 | 1 | -0 | 1 | -4 | 1 |
| EPS (₹ per share) | -1.21 | -0.21 | -0.81 | 0.12 | -0.02 | 0.09 | -0.41 | 0.12 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 71 | 92 | 102 |
| Expenses | 72 | 96 | 99 |
| Operating profit | -1 | -4 | 3 |
| Other income | 4 | 0 | 3 |
| Interest | 0 | 1 | 1 |
| Depreciation | 6 | 8 | 8 |
| Profit before tax | -3 | -12 | -2 |
| Net profit | -4 | -20 | -2 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 65 | 78 | 78 | 86 | 86 | 87 |
| Reserves | 121 | 95 | 91 | 87 | 88 | 87 |
| Borrowings | 6 | 3 | 5 | 6 | 11 | 15 |
| Other liabilities | 30 | 52 | 22 | 25 | 23 | 27 |
| Total liabilities | 222 | 228 | 197 | 204 | 207 | 216 |
| Fixed assets | 59 | 65 | 90 | 90 | 88 | 89 |
| Capital work in progress | 20 | 9 | 1 | 0 | 3 | 4 |
| Investments | 4 | 3 | 3 | 4 | 5 | 5 |
| Other assets | 140 | 152 | 102 | 110 | 111 | 118 |
| Total assets | 222 | 228 | 197 | 204 | 207 | 216 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 12 | -9 | 23 | -9 | -5 | -3 |
| Cash from investing | -2 | -5 | 10 | -21 | -20 | -12 |
| Cash from financing | 10 | -2 | -1 | 2 | 23 | 11 |
| Net cash flow | 20 | -16 | 32 | -28 | -2 | -3 |
| Free cash flow | 5 | -16 | 21 | -33 | -14 | -15 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 213 | 77 | 80 | 66 | 52 | 60 |
| Inventory days | 97 | 114 | 128 | 176 | 151 | 156 |
| Days payable | 128 | 130 | 197 | 197 | 140 | 174 |
| Cash conversion cycle | 182 | 61 | 11 | 46 | 63 | 42 |
| Working capital days | 272 | 217 | 41 | 51 | 47 | 45 |
| Return on capital employed | 1.0% | 1.0% | −2.0% | −2.0% | −5.0% | −1.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Where revenue comes from
The businesses behind the company’s reported revenue.
manufacturing business contributes 91.2% of reported segment revenue.
Year ended 31 Mar 2022 · Standalone
- manufacturing business 91.2%
₹79.91 crore
- other than manufacturing business 5.7%
₹4.98 crore
- retail business 3.1%
₹2.75 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| manufacturing business | 79.91 | 91.2% |
| other than manufacturing business | 4.98 | 5.7% |
| retail business | 2.75 | 3.1% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
How these numbers add up
- Total segment revenue
- ₹87.63 crore
- Intersegment adjustment
- ₹1.38 crore
- Net segment revenue
- ₹86.25 crore
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
Ownership
Who owns it
Public hold 63.03% as of Jun 2026; institutions cut 0.46 pts since Mar 2026.
- Promoters 33.85%
- Foreign institutions 3.14%
- Domestic institutions 0.00%
- Public 63.03%
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- +0.18 pp 1.18% held
- newly disclosed 0.02% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of JHS Svendgaard Laboratories Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 30.32% | unchanged | |
| 3.51% | unchanged | |
| 2.74% | unchanged | |
| 2.06% | unchanged | |
| FPI fund | 2.06% | unchanged |
| 2.06% | unchanged | |
| 2.06% | unchanged | |
| 2.06% | unchanged | |
| 1.51% | unchanged | |
| 1.18% | +0.18 pp | |
| FPI fund | 1.08% | −0.45 pp |
| 0.02% | newly disclosed |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for JHS Svendgaard Laboratories Limited
Free account: one company. Everything above stays public.
Write why you follow JHS Svendgaard Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Fast Moving Consumer Goods companies
Learn to analyse JHS Svendgaard Laboratories Limited
Guides on how to read this kind of business and the numbers that matter.